<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00465569</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00002102</org_study_id>
    <nct_id>NCT00465569</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Placebo-Controlled Study of Oral Milk Immunotherapy for Cow's Milk Allergy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of Oral Milk Immunotherapy for Cow's Milk Allergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if small oral doses of milk protein are safe and
      effective in decreasing sensitivity to cow's milk in allergic children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, clinical trial involving children aged 6 to 21 years
      with persistent cow's milk allergy. These children will be recruited from 2 sites (Johns
      Hopkins and Duke University) and will undergo initial screening and double-blind,
      placebo-controlled, food challenge (DBPCFC) to confirm threshold dose for reactivity to milk.
      Patients will be treated with milk oral immunotherapy (OIT) or placebo for 22-30 weeks. Those
      who reach an adequate maintenance dose for OIT will undergo a second DBPCFC. Those who
      develop desensitization will continue with daily milk intake and undergo a third DBPCFC.
      Those in the treatment group who are not desensitized will return to strict avoidance. Those
      in placebo group will be offered to begin treatment or continue with strict milk avoidance.
      Symptom and diet information will be collected initially and at regular intervals. Bloodwork,
      skin prick tests (SPTs), pulmonary function tests (PFTs), and oral secretion samples will be
      done initially and at periodic intervals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Median Milk Threshold Dose Inducing a Reaction</measure>
    <time_frame>Baseline and 23 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Cow Milk-IgE</measure>
    <time_frame>Baseline and 23 weeks</time_frame>
    <description>IgE is measured in kilounits per liter (kU/L). Measurements were obtained at Baseline and at 23 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Cow Milk Immunoglobulin G4 (IgG4)</measure>
    <time_frame>Baseline and 23 weeks</time_frame>
    <description>IgG4 is measured in ug/mL. Measurements were obtained at Baseline and at 23 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Milk Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-measured doses of dry, nonfat powered milk prepared by the clinical research-registered dieticians</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cow's milk powder</intervention_name>
    <description>Milk powder given orally in escalating doses to a goal of 500 mg for approximately 23 weeks</description>
    <arm_group_label>Active Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide signed informed consent (by parent or legal guardian if the subject is a
             minor) and informed assent if applicable

          -  Age 6 to 21 years

          -  Must have history of symptomatic reactivity to cow's milk (eczema, urticaria,
             upper/lower resp., GI, other associated rash, oral symptoms)

          -  History of positive skin prick test (wheal &gt;/= histamine control) or
             milk-Immunoglobulin E (IgE)&gt;0.35 kilounits per liter (kU/L)

          -  Positive DBPCFC

          -  All females of child bearing age must be using appropriate birth control

        Exclusion Criteria:

          -  History of anaphylaxis requiring hospitalization

          -  History of intubation related to asthma

          -  Has the ability to tolerate &gt;2.4gram of milk protein at initial DBPCFC

          -  Has a history of allergy to any component of vehicle

          -  Pregnancy (need negative test)

          -  Viral upper respiratory infection (URI) or gastroenteritis within 7days of OFC (OFC
             needs to be rescheduled)

          -  Has pulmonary function tests &lt;80% of predicted (FEV1) or clinical history consistent
             with moderate persistent asthma

          -  Currently taking greater than medium dose inhaled corticosteroid (&gt;400mcg/day
             fluticasone or fluticasone equivalent if &lt;/=12yo or &gt;600mcg/day if &gt;12 years old)

          -  Antihistamine within 1 week prior to skin testing or food challenges (Skin testing
             and/or food challenge needs to be rescheduled)

          -  Systemic corticosteroid within 4 weeks prior to baseline visit

          -  Receiving omalizumab, beta-blocker, Angiotensin-converting enzyme (ACE) inhibitor or
             tricyclic antidepressant therapy

          -  Chronic disease (other than asthma, atopic dermatitis, rhinitis) requiring therapy
             (e.g., heart disease, diabetes)

          -  Participation in any interventional study for treatment of a food allergy in the past
             12 months

          -  Severe reaction at initial DBPCFC, defined as:

             i. Life-threatening anaphylaxis ii. Requires overnight hospitalization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A Wood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Buchanan AD, Green TD, Jones SM, Scurlock AM, Christie L, Althage KA, Steele PH, Pons L, Helm RM, Lee LA, Burks AW. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol. 2007 Jan;119(1):199-205. Epub 2006 Oct 27.</citation>
    <PMID>17208602</PMID>
  </reference>
  <reference>
    <citation>Meglio P, Bartone E, Plantamura M, Arabito E, Giampietro PG. A protocol for oral desensitization in children with IgE-mediated cow's milk allergy. Allergy. 2004 Sep;59(9):980-7.</citation>
    <PMID>15291907</PMID>
  </reference>
  <reference>
    <citation>Enrique E, Pineda F, Malek T, Bartra J, Basagaña M, Tella R, Castelló JV, Alonso R, de Mateo JA, Cerdá-Trias T, San Miguel-Moncín Mdel M, Monzón S, García M, Palacios R, Cisteró-Bahíma A. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol. 2005 Nov;116(5):1073-9. Epub 2005 Oct 3.</citation>
    <PMID>16275379</PMID>
  </reference>
  <results_reference>
    <citation>Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S, Hamilton RG, Matsui EC, Burks AW, Wood RA. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol. 2008 Dec;122(6):1154-60. doi: 10.1016/j.jaci.2008.09.030. Epub 2008 Oct 25.</citation>
    <PMID>18951617</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2007</study_first_submitted>
  <study_first_submitted_qc>April 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2007</study_first_posted>
  <results_first_submitted>February 17, 2017</results_first_submitted>
  <results_first_submitted_qc>April 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 20, 2017</results_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Food Allergy</keyword>
  <keyword>Oral Immunotherapy</keyword>
  <keyword>Immunoglobulin E</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Milk Hypersensitivity</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Children between the ages of 6 and 21 years with a known history of IgE-mediated milk allergy were recruited from the pediatric allergy clinics at the Johns Hopkins University Hospital, Baltimore, Maryland, and Duke University Medical Center, Durham, North Carolina.</recruitment_details>
      <pre_assignment_details>Eligibility criteria were a positive skin prick test (SPT) response to milk extract (wheal ≥ histamine control) or milk immunoglobulin E (IgE) level of &gt; 0.35 kilounits per liter (kU/L) and a positive milk challenge result at baseline defined as reacting with clear signs, symptoms, or both to a cumulative dose of 2.5 g or less of milk protein.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Treatment</title>
          <description>Pre-measured doses of dry, nonfat powered milk prepared by the clinical research-registered dieticians
cow's milk powder: Milk powder given orally in escalating doses to a goal of 500 mg for approximately 23 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Pre-measured doses of ProFree, a dry, milk free powder</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>persistent eczema during dose escalation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Treatment</title>
          <description>Pre-measured doses of dry, nonfat powered milk prepared by the clinical research-registered dieticians
cow's milk powder: Milk powder given orally in escalating doses to a goal of 500 mg for approximately 23 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.3" spread="3.3"/>
                    <measurement group_id="B2" value="10.2" spread="3.3"/>
                    <measurement group_id="B3" value="9.5" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of eczema</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current eczema</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of asthma</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current asthma</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of other food allergy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Median Milk Threshold Dose Inducing a Reaction</title>
        <time_frame>Baseline and 23 weeks</time_frame>
        <population>One participant in the active treatment arm did not complete the study due to persistent eczema during dose escalation. The median milk threshold dose in both groups was 40 with a full range of 40-1340 at the baseline challenge.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>Pre-measured doses of dry, nonfat powered milk prepared by the clinical research-registered dieticians
cow's milk powder: Milk powder given orally in escalating doses to a goal of 500 mg for approximately 23 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>The Median Milk Threshold Dose Inducing a Reaction</title>
          <population>One participant in the active treatment arm did not complete the study due to persistent eczema during dose escalation. The median milk threshold dose in both groups was 40 with a full range of 40-1340 at the baseline challenge.</population>
          <units>miligrams</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="40" upper_limit="1340"/>
                    <measurement group_id="O2" value="40" lower_limit="40" upper_limit="1340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 23 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5100" lower_limit="2500" upper_limit="8100"/>
                    <measurement group_id="O2" value="0" lower_limit="-1300" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Cow Milk-IgE</title>
        <description>IgE is measured in kilounits per liter (kU/L). Measurements were obtained at Baseline and at 23 weeks</description>
        <time_frame>Baseline and 23 weeks</time_frame>
        <population>One participant in the active treatment arm did not complete the study due to persistent eczema during dose escalation</population>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>Pre-measured doses of dry, nonfat powered milk prepared by the clinical research-registered dieticians
cow's milk powder: Milk powder given orally in escalating doses to a goal of 500 mg for approximately 23 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Cow Milk-IgE</title>
          <description>IgE is measured in kilounits per liter (kU/L). Measurements were obtained at Baseline and at 23 weeks</description>
          <population>One participant in the active treatment arm did not complete the study due to persistent eczema during dose escalation</population>
          <units>percentage of change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="-50" upper_limit="64"/>
                    <measurement group_id="O2" value="-5" lower_limit="-13" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Cow Milk Immunoglobulin G4 (IgG4)</title>
        <description>IgG4 is measured in ug/mL. Measurements were obtained at Baseline and at 23 weeks</description>
        <time_frame>Baseline and 23 weeks</time_frame>
        <population>One participant in the active treatment arm did not complete the study due to persistent eczema during dose escalation</population>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>Pre-measured doses of dry, nonfat powered milk prepared by the clinical research-registered dieticians
cow's milk powder: Milk powder given orally in escalating doses to a goal of 500 mg for approximately 23 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Cow Milk Immunoglobulin G4 (IgG4)</title>
          <description>IgG4 is measured in ug/mL. Measurements were obtained at Baseline and at 23 weeks</description>
          <population>One participant in the active treatment arm did not complete the study due to persistent eczema during dose escalation</population>
          <units>percentage of change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="767" lower_limit="29" upper_limit="1321"/>
                    <measurement group_id="O2" value="14" lower_limit="-14" upper_limit="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Active Treatment</title>
          <description>Adverse event information is based on percentages of doses. There were 2437 total doses in the active treatment arm with a median of 177 and a range of 155-242 per participant. There was a total of 13 participants in the active treatment arm who were analyzed for the Adverse Events data reported below.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Adverse event information is based on percentages of doses. There were 1193 total doses in the placebo arm with a median of 171 and a range of 152-199 per participant. There was a total of 7 participants in the placebo arm who were analyzed for the Adverse Events data reported below.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1193"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2437"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1193"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1107" subjects_at_risk="2437"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="1193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="458" subjects_affected="458" subjects_at_risk="2437"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="1193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple systems</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="2437"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory</sub_title>
                <counts group_id="E1" events="198" subjects_affected="198" subjects_at_risk="2437"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="1193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Local symptoms</sub_title>
                <counts group_id="E1" events="870" subjects_affected="870" subjects_at_risk="2437"/>
                <counts group_id="E2" events="104" subjects_affected="104" subjects_at_risk="1193"/>
              </event>
              <event>
                <sub_title>Skin</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="2437"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1193"/>
              </event>
              <event>
                <sub_title>Eczema flare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2437"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1193"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert A. Wood, MD</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-955-5883</phone>
      <email>rwood@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

